The economic burden of rare diseases is 10 times higher than that of mass market diseases
The economic burden of rare diseases based on direct, indirect and mortality-related costs is 10 times greater than the burden of mass market diseases, such as diabetes and cardiovascular disease, and this burden increases when no treatment…